Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
Maleki-Yazdi, M. Reza, Kaelin, Thomas, Richard, Nathalie, Zvarich, Michael, Church, Alison
Published in Respiratory medicine (01.12.2014)
Published in Respiratory medicine (01.12.2014)
Get full text
Journal Article
Primary Care Severe Asthma Registry and Education Project (PCSAR-EDU): Phase 1 – an e-Delphi for registry definitions and indices of clinician behaviour
D'Urzo, Katrina A, Tamari, Itamar E, Chapman, Kenneth R, Maleki-Yazdi, M Reza, Greiver, Michelle, Upshur, Ross EG, Biro, Lana, O'Neill, Braden, Moineddin, Rahim, Aliarzadeh, Babak, Kulasegaram, Kulamakan, To, Teresa, D'Urzo, Anthony D
Published in BMJ open (24.03.2022)
Published in BMJ open (24.03.2022)
Get full text
Journal Article
Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
D’Urzo, Anthony, Chapman, Kenneth R., Donohue, James F., Kardos, Peter, Maleki-Yazdi, M. Reza, Price, David
Published in Pulmonary therapy (01.06.2019)
Published in Pulmonary therapy (01.06.2019)
Get full text
Journal Article
Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
Maleki-Yazdi, M. Reza, Singh, Dave, Anzueto, Antonio, Tombs, Lee, Fahy, William A., Naya, Ian
Published in Advances in therapy (01.01.2017)
Published in Advances in therapy (01.01.2017)
Get full text
Journal Article
Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD
Maltais, François, Hamilton, Alan, Voß, Florian, Maleki-Yazdi, M. Reza
Published in Advances in therapy (01.04.2019)
Published in Advances in therapy (01.04.2019)
Get full text
Journal Article
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2 -agonist, for 4 weeks in patients with chronic obstructive pulmonary disease
Maleki-Yazdi, M. Reza, Beck, Ekkehard, Hamilton, Alan L, Korducki, Lawrence, Koker, Paul, Fogarty, Charles
Published in Respiratory medicine (01.05.2015)
Published in Respiratory medicine (01.05.2015)
Get full text
Journal Article
Importance de distinguer l'asthme de la maladie pulmonaire obstructive chronique en première ligne
D'Urzo, Anthony D, Price, David, Kardos, Peter, Maleki-Yazdi, M Reza
Published in Canadian family physician (01.09.2021)
Published in Canadian family physician (01.09.2021)
Get full text
Journal Article
Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease
Aalbers, René, Maleki-Yazdi, M. Reza, Hamilton, Alan, Waitere-Wijker, Stella, Zhao, Yihua, Amatto, Valeria C., Schmidt, Olaf, Bjermer, Leif
Published in Advances in therapy (01.09.2015)
Published in Advances in therapy (01.09.2015)
Get full text
Journal Article
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
Reza Maleki-Yazdi, M., Molimard, Mathieu, Keininger, Dorothy L., Gruenberger, Jean-Bernard, Carrasco, Joao, Pitotti, Claudia, Sauvage, Elsa, Chehab, Sara, Price, David
Published in Applied health economics and health policy (01.10.2016)
Published in Applied health economics and health policy (01.10.2016)
Get full text
Journal Article
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
D'Urzo, Anthony D, Cazzola, Mario, Hanania, Nicola A, Buhl, Roland, Maleki-Yazdi, M Reza
Published in International journal of chronic obstructive pulmonary disease (01.01.2018)
Published in International journal of chronic obstructive pulmonary disease (01.01.2018)
Get full text
Journal Article
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol
Koch, Andrea, Watz, Henrik, Maleki-Yazdi, M. Reza, Bothner, Ulrich, Tetzlaff, Kay, Voß, Florian, McGarvey, Lorcan
Published in NPJ primary care respiratory medicine (23.10.2017)
Published in NPJ primary care respiratory medicine (23.10.2017)
Get full text
Journal Article
Evolving therapies in chronic obstructive pulmonary disease
D'Urzo, Anthony D, Maleki-Yazdi, M Reza, McIvor, R Andrew
Published in Clinical practice (London, England) (01.05.2014)
Published in Clinical practice (London, England) (01.05.2014)
Get full text
Journal Article
Importance de distinguer l’asthme de la maladie pulmonaire obstructive chronique en première ligne
D’Urzo, Anthony D., Price, David, Kardos, Peter, Maleki-Yazdi, M. Reza
Published in Canadian family physician (01.09.2021)
Published in Canadian family physician (01.09.2021)
Get full text
Journal Article
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting [beta]2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease
Maleki-Yazdi, M Reza, Beck, Ekkehard, Hamilton, Alan L, Korducki, Lawrence, Koker, Paul, Fogarty, Charles
Published in Respiratory medicine (01.05.2015)
Published in Respiratory medicine (01.05.2015)
Get full text
Journal Article
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat ® device for maintenance treatment of COPD: comparison with the long-acting β 2 -agonist formoterol
Koch, Andrea, Watz, Henrik, Maleki-Yazdi, M Reza, Bothner, Ulrich, Tetzlaff, Kay, Voß, Florian, McGarvey, Lorcan
Published in NPJ primary care respiratory medicine (23.10.2017)
Get full text
Published in NPJ primary care respiratory medicine (23.10.2017)
Journal Article
Cost Effectiveness of the Long-Acting [Beta]^sub 2^-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
Maleki-Yazdi, M Reza, Molimard, Mathieu, Keininger, Dorothy L, Gruenberger, Jean-Bernard, Carrasco, Joao, Pitotti, Claudia, Sauvage, Elsa, Chehab, Sara, Price, David
Published in Applied health economics and health policy (01.10.2016)
Published in Applied health economics and health policy (01.10.2016)
Get full text
Journal Article